Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients (RACHEL)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00931320
First received: June 30, 2009
Last updated: October 23, 2009
Last verified: October 2009
  Purpose

An observational, non-interventional, multi-centre study to provide further information on the ratio of LDL-C to HDL-C improvement after statin treatment in Korean patients group.


Condition
Dyslipidemias

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluate current LDL/HDL ratio in Korean patients (between baseline & after treatment) [ Time Frame: After Treatment : at least 4 weeks before statin taking /Baseline : no limitation. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate difference of LDL/HDL ratio among different statins & dosages (between baseline & after treatment) [ Time Frame: After Treatment : at least 4 weeks before statin taking / Baseline : no limitation. ] [ Designated as safety issue: No ]

Estimated Enrollment: 3000
Study Start Date: July 2009
Study Completion Date: September 2009
Groups/Cohorts
3000 patients
Who have at least made 1 visit to the outpatient clinic within previous 6 months .

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Who have at least made 1 visit to the outpatient clinic within previous 6 months .

Criteria

Inclusion Criteria:

  • Subjects who are taking lipid-lowering medication after diagnosed as dyslipidaemia
  • Subjects who have at least made 1 visit to the outpatient clinic within previous 6 months
  • Subjects who have records of both LDL-C and HDL-C before & after statin treatment (at least four weeks after statin taking)

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide their examination and lab result of medical chart.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00931320

Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Hyunah Caroline Choi AstraZeneca Korea
  More Information

No publications provided

Responsible Party: Hyunah Caroline, Choi / CV TA Physician, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00931320     History of Changes
Other Study ID Numbers: NIS-CKR-DUM-2009/3
Study First Received: June 30, 2009
Last Updated: October 23, 2009
Health Authority: Korea: Food and Drug Administration

Keywords provided by AstraZeneca:
Ratio improvement
LDL-C
HDL-C
Ratio of Low Density Lipoprotein Cholesterol to High Density Lipoprotein Cholesterol Improvement
High Density Lipoprotein Cholesterol

Additional relevant MeSH terms:
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on August 28, 2014